pcn poster

Posters

Assessing Clinical Practice Patterns in Treatment-Resistant Schizophrenia

Goal: To assess physicians’ practice patterns in recognition, management, and knowledge of emerging treatments for treatment-resistant schizophrenia (TRS). Methods: • A 26-question a...

John Maeglin , MBA;

Marcello Morgan , MD, MPH;

John Kane , MD;

03/01/2019

Antipsychotic Treatment Communication Patterns: Predictors and Follow-up Risk

Discussing treatment compliance is challenging when patients have serious mental illness. Little is known about compliance-related discussions between healthcare providers and patients. ...

Heidi Waters , PhD, MBA;

Carolyn Martin , MSW;

John P. White , MD, DPM, MS;

Eleena Koep , MS;

Angela Belland , BS ;

Felicia Forma , BSc;

03/01/2019

Antidepressant, Stimulant/Wake Promoting Agent, and Sedative/Hypnotic Use in Patients with Obstructive Sleep Apnea in the United States

OBJECTIVE: To assess the use of antidepressants, stimulants (amphetamine/methylphenidate), wake promoting agents (WPAs; modafinil/armodafinil), and sedative/hypnotics in patients with obs...

Maurice Ohayon , MD, DSc, PhD;

Susan Gibson , RPh, MBA;

Brian Scheckner , PharmD;

Cristina Milesi , PhD;

Judith Profant , PhD, MS;

03/01/2019

An Ongoing Randomized Double-blind Active-controlled Study of Starting Aripiprazole Lauroxil with a 1-Day Initiation Regimen in Acutely Ill Subjects with Schizophrenia: Rationale, Study Design, and Patient Population at Baseline

Recent FDA approvals provide physicians the opportunity to initiate long-acting injectable (LAI) antipsychotics in acute settings, but there is limited research comparing the efficacy an...

Amy Claxton , PhD;

Yangchun Du , PhD;

Peter J. Weiden , MD, PhD;

03/01/2019

Adolescent Non-Medical Use of Prescription Stimulants: Prevalence, Route and Drug Acquisition

Prescription stimulants often prescribed for attention deficit hyperactivity disorder have been highlighted by regulatory agencies and others as emerging drugs of misuse/abuse. Non-medica...

Stephen V. Faraone , PhD;

Jeffrey Newcorn , MD;

Jody Green , PhD;

Natasha Oyedele , MPH, MSc;

Stephen Butler , PhD;

03/01/2019

A Survey of the Burden of Attention-Deficit/Hyperactivity Disorder on Daily Activities and Relationships in Adolescents

Background: Adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD) face significant disease burden. This cross-sectional survey evaluated ADHD burden from the perspect...

Michael Andreini , BA;

Steven Blahut , MA, PhD;

Eitan Shimko , MS;

Robert Stolper ;

Peter Jensen , MD;

Sepehr Farahbakhshian , MS;

Brigitte Robertson , MD;

03/01/2019

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of SHP465 Mixed Amphetamine Salts Extended-Release in Children and Adolescents With ADHD: Exploratory Analyses by Age

Objectives: To evaluate SHP465 mixed amphetamine salts (MAS) extended-release efficacy, safety, and tolerability by age group in children and adolescents with attention-deficit/hyperactiv...

Ann Childress , MD;

Ming Yu , MD, PhD;

Brian Yan , PhD;

Brigitte Robertson , MD;

03/01/2019

A Post Hoc Analysis of Relationships Between Executive Function Improvement and ADHD Symptom Improvement With Lisdexamfetamine Dimesylate in Adults With ADHD and Executive Function Deficits

Background: Executive function (EF) deficits are not generally considered synonymous with attention-deficit/hyperactivity disorder (ADHD). Evidence suggests stimulants improve ADHD sympto...

Thomas Brown , PhD;

Victor Otcheretko , MD;

Brigitte Robertson , MD;

Jie Chen , MS;

03/01/2019

A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients With Acute Exacerbation of Schizophrenia

Background: ALKS 3831, under development for the treatment of schizophrenia, is composed of olanzapine and samidorphan. In a prior study, samidorphan mitigated olanzapine-associated weigh...

Ying Jiang , PhD;

Bernard Silverman , MD;

Lauren DiPetrillo , PhD;

Steven Potkin , MD;

Adam Simmons , MPH;

David McDonnell , MD;

03/01/2019

A Phase 3 Non-Inferiority Study Comparing Paliperidone Palmitate 1-Month vs 3-Month Long-Acting Injectables for Negative Symptom Improvement in Schizophrenia

Background: Negative symptoms of schizophrenia are predictors of long-term disability. Paliperidone palmitate 3-month formulation (PP3M) provides a sustained release of paliperidone, perm...

Edward S. Kim , MD, FACP, MBA;

Arun K. Singh , MD, PhD, MCh, MNAMS;

Katalin Pungor , PhD;

Maju Mathews , MD;

Jagadish Gogate , PhD;

Srihari Gopal , MD;

03/01/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products